Research ExplorerPublicationsNeutron therapy, prognostic factors and dedifferentiation of...

Neutron therapy, prognostic factors and dedifferentiation of adenoid cystic carcinomas (ACC) of salivary glands

Standard

Neutron therapy, prognostic factors and dedifferentiation of adenoid cystic carcinomas (ACC) of salivary glands. / Brackrock, Sophie; Krüll, Andreas; Röser, Kerstin; Schwarz, Rudolf; Riethdorf, Lutz; Alberti, Winfried.

In: ANTICANCER RES, Vol. 25, No. 2B, 04.05.2005, p. 1321-6.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Brackrock, S, Krüll, A, Röser, K, Schwarz, R, Riethdorf, L & Alberti, W 2005, 'Neutron therapy, prognostic factors and dedifferentiation of adenoid cystic carcinomas (ACC) of salivary glands', ANTICANCER RES, vol. 25, no. 2B, pp. 1321-6.

APA

Brackrock, S., Krüll, A., Röser, K., Schwarz, R., Riethdorf, L., & Alberti, W. (2005). Neutron therapy, prognostic factors and dedifferentiation of adenoid cystic carcinomas (ACC) of salivary glands. ANTICANCER RES, 25(2B), 1321-6.

Vancouver

Brackrock S, Krüll A, Röser K, Schwarz R, Riethdorf L, Alberti W. Neutron therapy, prognostic factors and dedifferentiation of adenoid cystic carcinomas (ACC) of salivary glands. ANTICANCER RES. 2005 May 4;25(2B):1321-6.

Bibtex

@article{357217fd2d6c476cb456be6c5ada31b0,
title = "Neutron therapy, prognostic factors and dedifferentiation of adenoid cystic carcinomas (ACC) of salivary glands",
abstract = "PURPOSE: Analysis of the efficacy of fast neutron radiotherapy in the treatment of adenoid cystic carcinomas (ACC) of the salivary glands, identification of prognostic variables and dedifferentiation after radiotherapy.PATIENTS AND METHODS: Histological slides of primary and recurrent lesions of 71 patients were reviewed to confirm the diagnosis and to analyse subtypes. Median follow-up was 52 months. Local control rate and overall survival were analysed in multivariate analysis. Complications are also described.RESULTS: Primary vs. recurrent therapy (p=0.001), margin-status (p=0.01) and subtype (p=0.019) influenced overall survival. Primary vs. recurrent therapy (p=0.001), margin-status (p=0.018) and T-stage (p=0.043) influenced local control rate. Dedifferentiation was seen in only 1/17 cases.CONCLUSION: The calculated prognostic factors illustrate the importance of a radical primary therapy. Histological subtype is a significant additional factor for overall survival and, in case of dedifferentiation, it is a strong predictor of a detrimental outcome.",
keywords = "Adult, Aged, Carcinoma, Adenoid Cystic, Cell Differentiation, Fast Neutrons, Female, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Metastasis, Neoplasm Recurrence, Local, Prognosis, Retrospective Studies, Salivary Gland Neoplasms, Survival Rate, Time Factors, Journal Article",
author = "Sophie Brackrock and Andreas Kr{\"u}ll and Kerstin R{\"o}ser and Rudolf Schwarz and Lutz Riethdorf and Winfried Alberti",
year = "2005",
month = may,
day = "4",
language = "English",
volume = "25",
pages = "1321--6",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2B",

}

RIS

TY - JOUR

T1 - Neutron therapy, prognostic factors and dedifferentiation of adenoid cystic carcinomas (ACC) of salivary glands

AU - Brackrock, Sophie

AU - Krüll, Andreas

AU - Röser, Kerstin

AU - Schwarz, Rudolf

AU - Riethdorf, Lutz

AU - Alberti, Winfried

PY - 2005/5/4

Y1 - 2005/5/4

N2 - PURPOSE: Analysis of the efficacy of fast neutron radiotherapy in the treatment of adenoid cystic carcinomas (ACC) of the salivary glands, identification of prognostic variables and dedifferentiation after radiotherapy.PATIENTS AND METHODS: Histological slides of primary and recurrent lesions of 71 patients were reviewed to confirm the diagnosis and to analyse subtypes. Median follow-up was 52 months. Local control rate and overall survival were analysed in multivariate analysis. Complications are also described.RESULTS: Primary vs. recurrent therapy (p=0.001), margin-status (p=0.01) and subtype (p=0.019) influenced overall survival. Primary vs. recurrent therapy (p=0.001), margin-status (p=0.018) and T-stage (p=0.043) influenced local control rate. Dedifferentiation was seen in only 1/17 cases.CONCLUSION: The calculated prognostic factors illustrate the importance of a radical primary therapy. Histological subtype is a significant additional factor for overall survival and, in case of dedifferentiation, it is a strong predictor of a detrimental outcome.

AB - PURPOSE: Analysis of the efficacy of fast neutron radiotherapy in the treatment of adenoid cystic carcinomas (ACC) of the salivary glands, identification of prognostic variables and dedifferentiation after radiotherapy.PATIENTS AND METHODS: Histological slides of primary and recurrent lesions of 71 patients were reviewed to confirm the diagnosis and to analyse subtypes. Median follow-up was 52 months. Local control rate and overall survival were analysed in multivariate analysis. Complications are also described.RESULTS: Primary vs. recurrent therapy (p=0.001), margin-status (p=0.01) and subtype (p=0.019) influenced overall survival. Primary vs. recurrent therapy (p=0.001), margin-status (p=0.018) and T-stage (p=0.043) influenced local control rate. Dedifferentiation was seen in only 1/17 cases.CONCLUSION: The calculated prognostic factors illustrate the importance of a radical primary therapy. Histological subtype is a significant additional factor for overall survival and, in case of dedifferentiation, it is a strong predictor of a detrimental outcome.

KW - Adult

KW - Aged

KW - Carcinoma, Adenoid Cystic

KW - Cell Differentiation

KW - Fast Neutrons

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Multivariate Analysis

KW - Neoplasm Metastasis

KW - Neoplasm Recurrence, Local

KW - Prognosis

KW - Retrospective Studies

KW - Salivary Gland Neoplasms

KW - Survival Rate

KW - Time Factors

KW - Journal Article

M3 - SCORING: Journal article

C2 - 15865085

VL - 25

SP - 1321

EP - 1326

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 2B

ER -